

Attorney Docket No. 60427 (72021)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: R. Bakthavatchalam et al.

U.S.S.N.: 10/735,607

Art Unit: 1712

FILED: December 12, 2003

Examiner: Unknown

FOR: 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to Commissioner for Patents, Alexandria VA 22313-1450 on April 16, 2004.

By: Michelle P. Chicos
Michelle P. Chicos

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Date: April 16, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. ☐ The following additional information is provided for the Examiner's consideration:

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)

(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
- c. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):

(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☐ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
- or
- b. ☐ See the certification below. No fee is required.

VI. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(d):
(check both boxes if applicable)

before payment of the Issue Fee (See 37 C.F.R. § 1.97(d).

- a. ☐ See the certification below; and
- b. ☐ A fee in the amount of \$180.00 is enclosed as required by 37 C.F.R. § 1.17(p).

VII. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.


☐ Please charge Deposit Account No. 04-1105 in the amount of _____ for the above-indicated fee. A triplicate copy of this paper is attached.

☒ No fee is required.

However, if any fee is required, e.g., due to issuance of a Final Office Action, please charge the required fee to Deposit Account No. 04-1105, and consider this paper as a conditional petition under 37 CFR 1.97(d).

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,




John B. Alexander, Ph.D. (Reg. No. 48,399)
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205

Date: April 16, 2004

Tel: (617) 439-4444

Customer No. 21874

BOS2_439997.1

**FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT**ATTY DOCKET NO.
60427 (72021)SERIAL NO.
10/735,607

APPLICANT(S): R. Bakthavatchalam et al.

FILING DATE:
December 12, 2003ART UNIT:
1712**UNITED STATES PATENT DOCUMENTS**

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILE DATE IF APPR
	AA	6,413,971	07/2002	Arnold et al.			
	AB	6,399,602	06/2002	Barker et al.			
	AC	6,395,733	05/2002	Arnold et al.			
	AD	6,391,874	05/2002	Cockerill et al.			
	AE	6,251,912	06/2001	Wissner et al.			
	AF	6,248,771	06/2001	Shenoy et al.			
	AG	6,207,669	05/2001	Cockerill et al.			
	AH	6,174,889	01/2001	Cockerill et al.			
	AI	6,169,091	01/2001	Cockerill et al.			
	AJ	5,939,421	08/1999	Palanki et al.			
	AK	5,814,630	09/1998	Barker et al.			
	AL	5,420,135	05/1995	Brown et al.			
	AM	5,064,833	11/1991	Ife et al.			
	AN	6,225,318	10/1996	Sobolov-Jaynes et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLISHED DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
	BA	WO 02/22601 A1	03/2002	PCT			
	BB	WO 01/21597 A1	03/2001	PCT			
	BC	WO 01/21596 A1	03/2001	PCT			
	BD	WO 01/21595 A1	03/2001	PCT			
	BE	WO 01/21594 A1	03/2001	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

Examiner:	Date:
-----------	-------

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.

60427 (72021)

SERIAL NO.

10/735,607

APPLICANT(S): R. Bakthavatchalam et al.

FILING DATE:

December 12, 2003

ART UNIT:

1712

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILE DATE IF APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLISHED DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
	BF	WO 01/04111 A1	01/2001	PCT			
	BG	WO 00/23444	04/2000	PCT			
	BH	WO 99/35146	07/1999	PCT			
	BI	WO 96/09294	03/1996	PCT			
	BJ	WO 95/15758	06/1995	PCT			
	BK	WO 89/05297	06/1989	PCT			
	BL	EP 1 229 025 A1	08/2002	EPO			
	BM	WO 03/62209	07/2003	EPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	CA	Temple et al., "Synthesis of Potential Antimalarial Agents. II. 6,8-Disubstituted Pyrido[2,3-b]pyrazines," J. Med. Chem. 11:1216-1218 (1968).

Examiner:

Date: